SaleMetabolic & GLP-1
Retatrutide
Next-generation GLP receptor agonist studied for metabolic signaling and nutrient partitioning pathways
RETA-CA-26E-0199.637%
11.76 mg / 10 mg
$60.00$70.00CAD

Vasoactive Intestinal Peptide
VIP is a 28–amino acid neuropeptide studied in research for vasodilatory, neuroendocrine, and immunomodulatory signaling.
Mix & Match
1 vial — no vial discount yet.
Add 2 more vials for 5% off.
After that, 10% at 5 vials, 20% at 10 vials.
🔬 This product is coming soon — ordering is not yet available.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
VIP is a 28–amino acid neuropeptide studied in research for vasodilatory, neuroendocrine, and immunomodulatory signaling.
Experimental models examine its receptor interactions (VPAC1/VPAC2) and downstream physiological pathways under controlled conditions.
Third-party tested for purity, ID, quantity.
Coming Soon
The certificate of analysis for the 10mg lot is being finalised and will be published here as soon as the lab returns it.
Vasoactive intestinal peptide is a member of the secretin/glucagon peptide superfamily that signals through VPAC1 and VPAC2 receptors. Research has characterized its vasodilatory action, neuroendocrine roles, and immunomodulatory signaling across multiple systems.
Studies span cardiovascular, metabolic, and neuroimmune research frameworks under structured conditions.
VIP was isolated and characterized as a vasoactive peptide of intestinal origin, subsequently recognized as a broadly distributed neuropeptide.
Research has since examined its receptor biology and wide-ranging physiological roles.
Research into VIP focuses on VPAC-receptor signaling and neuroendocrine/immune regulation. Frameworks evaluate vasodilation, metabolic signaling, and neuroimmune endpoints under controlled conditions.
1 of the 4 areas below are addressed directly by a paper cited on this page.
Addressed on this page by Hou 2022. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
No paper cited on this page reports on vasodilation or cardiovascular. This heading marks where VIP Peptide is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
No paper cited on this page reports on neuroendocrine. This heading marks where VIP Peptide is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
No paper cited on this page reports on neuroimmune or axis. This heading marks where VIP Peptide is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
The references section of this page cites 3 primary papers published between 1986 and 2022 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for VIP Peptide, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
VIP Peptide is also referred to as VIP peptide.
VIP Peptide is commonly described online in connection with weight loss, appetite suppression and fat reduction. In the research literature the same compound is filed under VPAC1/VPAC2 receptor-signaling models, vasodilation and cardiovascular research and neuroendocrine signaling studies.
The 3 papers cited on this page, published between 1986 and 2022 describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Every lot of VIP Peptide is independently assayed before it is released, and the certificate for the lot shipped is published rather than summarised. Where a certificate for a current lot is not yet posted, the lot has not yet been released against it.
Researchers who buy VIP Peptide in Canada through Eppix Labs receive a batch-labelled vial whose certificate is published against that lot code, so the material can be matched to its analysis rather than to a generic specification.
VIP Peptide is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 28 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.
Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of vip. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Related
SaleMetabolic & GLP-1
Next-generation GLP receptor agonist studied for metabolic signaling and nutrient partitioning pathways
RETA-CA-26E-0199.637%
11.76 mg / 10 mg
$60.00$70.00CAD
SaleMetabolic & GLP-1
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$35.00$40.00CAD

Metabolic & GLP-1
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
10 mgSEMA-CA-26F-1099.504%
11.27 mg / 10 mg
$70.00CAD

Metabolic & GLP-1
This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
10 mgELOR-CA-26G-1099.810%
12.42 mg / 10 mg
$150.00CAD